5. Conclusion
Our study assessed the effects of non-adherence to edoxaban on PK and PD. We developed an appropriate remedial dosing strategy for NVAF patients based on the populational PK/PD model. Our simulation has shown that current EHRA recommendations may not be the optimal remedial dosing for patients with delayed or missed doses. Model-informed simulation is an accessible method for effectively addressing the remedial dosing strategy. In practice, clinicians can use our strategy and balance patients’ thrombosis and bleeding risk to determine the optimal remedial strategy.